Company intelligence / Profile preview

Atmo Biosciences

Box Hill, Victoria, Australiaatmobiosciences.com ↗

Ownership: Private
Development stage: Preclinical

Overview

The pivotal clinical study data published in March 2025 demonstrated the utility of the Atmo Gas Capsule for assessing gastrointestinal motility. Results support a forthcoming FDA submission. Earlier studies showed good correlation with gold-standard diagnostic methods and potential as a replacement for discontinued devices like SmartPill. The device has also shown promise in pilot studies for SIBO diagnosis and monitoring colonic fermentation changes in IBS patients.

Therapeutic areas: Gastroenterology
Modalities: Diagnostic device (ingestible gas-sensing capsule)
Industry: Metabolite Diagnostics

Partnerships

Otsuka Pharmaceutical Co., Ltd. (strategic investor/partner)RMIT University (licensing/research collaboration)

Beyond the preview

Go deeper on Atmo Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Atmo Biosciences.

Explore the full profile